The design of new generations of improved antibodies for immunotherapy should aim at Fc optimization to enhance the  ADCC process leading to the tumor cell lysis.

The goal is to increase the Fc affinity for FcgR present on the surface of tumor-infiltrating effector cell populations. 

With this goal in mind, Cisbio has developed several HTRF®-based cellular binding assays to efficiently and accurately measure the binding of the different subclasses of IgGs with the CD16a and other variants. 

These assays were validated using commercial sources of therapeutic antibodies.

We also evaluated the effect of antibody fucosylation on the FcgR interaction.